Bora Pharmaceuticals announced its February consolidated revenue of NT$1.33 billion, representing a 16.12% month-on-month increase. While year-on-year figures showed a 23.23% decline due to early-year fluctuations, the company confirmed that its Contract Development and Manufacturing Organization (CDMO) pipeline remains robust, with a US$264 million order book secured for the next 12 months.

• Market Sentiment Shifts: The revenue rebound in February is attributed to the dissipating "wait-and-see" atmosphere surrounding DLS (Gastroesophageal Reflux Disease) generics. Clients have resumed procurement momentum as pricing trends in the U.S. market stabilized.
• Overcoming Short-term Hurdles: The company identified two primary factors for the slower start in January: a routine 4-week annual maintenance shutdown at its Maryland (USA) sterile injectable plant and cautious inventory management by distributors. Both issues have since been resolved.
• 2026 Outlook: Bora plans to launch at least seven new generic products this year. Analysts noted that Bora’s CDMO portfolio spans complex dosage forms and high-barrier technologies, providing superior order visibility and client stickiness. With the integration of Upsher-Smith assets entering the scaling phase, the company anticipates a "gradually improving" performance for the remainder of the year.

Resource: 2.64億美元訂單在手 保瑞營運無虞